leaps_news_header_01

Health From treatment to cure

Exponential technology in health is enabling advances that once seemed impossible — restoring lost tissue function like dopaminergic neurons for patients suffering from Parkinson´s disease or tackling the organ shortage through xenotransplantation. Through our investments and collaborations, which are aligned with our areas of expertise, we target paradigm-shifting ideas in human health. We partner with the brightest minds in biotech. We are prepared to learn from failure. If even one of these ideas works, together we will transform the world for the better.

Agriculture From more to better

From data science and sensors to synthetic biology; emerging technologies are poised to fundamentally transform modern agriculture. We invest in companies pursuing breakthroughs that could decrease the intensive inputs of farming—energy, land, chemicals—while increasing productivity, nutrition, and quality. Nitrogen fixation, truly sustainable crop protection, and disruptive digital business models. The scale of agriculture is massive and our planet is diverse. Change will not happen overnight. The companies in our portfolio are a lighthouse. Through technology, science, and collaboration, we believe we can both nourish our expanding population and preserve our global ecosystem.

Health portfolio

eGenesis

November 2019
Learn more

Immunitas

November 2019
Learn more

One Drop

September 2019
Learn more

Arvinas

July 2019
Learn more

Pyxis Oncology

July 2019
Learn more

Century Therapeutics

July 2019
Learn more

Dewpoint

January 2019
Learn more

Khloris Biosciences

December 2018
Learn more

BlueRock Therapeutics

December 2016
Learn more

Casebia / CRISPR Therapeutics

February 2016
Learn more

Medopad

November 2012
Learn more
View more
egenesis_logo

eGenesis

Vision

eGenesis strives to create a world with no shortage of human transplantable organs.

Approach

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing the key virology and immunology hurdles that have impeded its advancement to date.

CEO: Paul Sekhri
Founder(s): Dr. Luhan Yang and Dr. George Church
First investment: November 2019

immunitas

Immunitas

Approach

Immunitas Therapeutics, founded by Longwood Fund, employs a single cell genomics platform to dissect the biology of immune cells in human tumors, thereby advancing discoveries directly from the bench into meaningful clinical improvements.

CEO: Jeff Goldberg
Founder(s): Kai Wucherpfennig M.D. Ph.D, Mario Suva M.D. Ph.D, Dane Wittrup PhD
First investment: November 2019

one_drop_logo

One Drop

Vision

Bring affordable, accessible diabetes care to everyone with diabetes and a smartphone.

Approach

One Drop is a diabetes management platform that works to harness mobile computing and data science to empower people with diabetes to live their best lives. The company offers a simple, modern, fully integrated solution that offers diabetics the confidence of knowing they can manage their medication today and in the future.

Founder(s): Jeff Dachis
First investment: September 2019

arvinas_logo

Arvinas

Approach

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening disease. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. PROTACs application in crop science is being explored through the joint venture, Oerth Bio.

CEO: John G. Houston, PhD
Founder(s): Craig Crews, PhD
First investment: July 2019

pyxis_logo

Pyxis Oncology

Approach

Pyxis Oncology develops antibody therapeutics to promote the body‘s immune response to cancer. Leveraging new insights into the tumor microenvironment, Pyxis works to enhance the immune response against cancer—even in tumor types that historically have not responded well to cancer immunotherapies.

CEO: Lara Sullivan, MD
Founder(s): David Steinberg, Shaan Gandhi (MD, DPhil), and John Flavin
First investment: July 2019

century_logo

Century Therapeutics

Vision

Century Therapeutics is working towards a world in which patients are no longer limited by first-generation cell therapies. The company wants to change cancer therapy for everyone by harnessing the power of adult stem cells to develop curative therapies.

Approach

Century’s genetically-engineered immune effector cell therapies are specifically designed to target hematologic and solid cancers and overcome barriers in autologous cell therapies.

CEO: Lalo Flores, PhD
First investment: July 2019

dewpoint_logo

Dewpoint

Approach

Dewpoint believes a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates — including cancer, neurodegeneration, and metabolic disease. Dewpoint scientists are working in Boston, MA, and Dresden, Germany, to translate condensate biology into treatments for the toughest diseases.

CEO: Amir Nashat
Founder(s): Anthony Hyman and Richard Young
First investment: January 2019

khloris

Khloris Biosciences

Approach

Khloris Biosciences is pioneering cancer vaccination. Khloris aims to revolutionize medical treatment and the prevention of cancer and other diseases by harnessing the unlimited immunotherapeutic potential of induced pluripotent stem cells for drug discovery, vaccines and cell therapies.

CEO: Lynne A. Bui, MD
Founder(s): Lynne A. Bui, MD and Joseph C. Wu, MD, PhD
First investment: December 2018

bluerock_logo

BlueRock Therapeutics

Vision

BlueRock is passionate about delivering on the promise of cellular and gene therapy, shaping the future of cellular medicine, and delivering new therapies to millions of patients with few treatment options.

Approach

BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ CELL+GENE™ platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications.

CEO: Emile Nuwaysir
Founder(s): Leaps by Bayer, Versant Ventures
First investment: December 2016

CasCrisp_logo

Casebia / CRISPR Therapeutics

Approach

Casebia / CRISPR Therapeutics is editing the genome to cure genetic diseases, translating a revolutionary technology into transformative therapies to change the lives of patients.

First investment: February 2016

medopad_logo

Medopad

Vision

A world where every person lives their life to the fullest.

Approach

Medopad aims to understand, treat, and ultimately prevent ill health by building a proactive healthcare category via a portfolio of digital biomarkers and digital therapeutics. Medopad offers a mix of medical expertise, technology modules, and services via 7 modular pillars to enable partners to discover, validate and commercialize digital health solutions.

CEO: Dan Vahdat
Founder(s): Dan Vahdat
First investment: November 2012

Agriculture portfolio

Oerth Bio

October 2019
Learn more

Grão Direto

March 2018
Learn more

Atomwise

February 2018
Learn more

Joyn Bio

September 2017
Learn more

New Leaf Symbiotics

July 2017
Learn more

Pairwise

July 2017
Learn more

FarmLead

December 2016
Learn more

Resson

April 2016
Learn more

Understory

January 2016
Learn more

Plant Response

August 2015
Learn more

Covercress

May 2015
Learn more

AgBiome

December 2012
Learn more
View more
oerth_logo

Oerth Bio

Approach

Pioneering PROTAC® technology in agriculture.

CEO: John Dombrosky
Founder(s): John G. Houston, PhD and Juergen Eckhardt
First investment: October 2019

GraoDireto_Logo

Grão Direto

Approach

Based in Brazil, Grão Direto is helping to create a new era for trading agricultural commodities by connecting farmers and grain buyers through technology. This includes not only supporting faster and safer trading, but also future opportunities in market data, financial products and services, logistics and more.

CEO: Alexandre Borges Silva
Founder(s): Alexandre Borges Silva, Pedro Paulo Paiva, and Frederico Marques
First investment: March 2018

atomwise_logo-dark

Atomwise

Approach

Atomwise patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve.

CEO: Abraham Heifets
Founder(s): Dr. Izhar Wallach and Abraham Heifets
First investment: February 2018

joynbio_logo

Joyn Bio

Vision

Engineering new microbial agricultural solutions to feed a global population.

Approach

With its microbe engineering platform, Joyn Bio is developing a portfolio of scientifically-validated biologicals for nitrogen fixation, pest control and disease management that meet the highest levels of performance and reliability.

CEO: Mike Miille
Founder(s): Leaps by Bayer, Gingko Bioworks
First investment: September 2017

newleaf-logo

New Leaf Symbiotics

Approach

NewLeaf Symbiotics has discovered in nature and optimized an important part of the plant's microbiome. Found on all plants, Methylotrophs, M-trophs are very special micro-organisms with unique features. Over many years of scientific study, development, and trials, NewLeaf has created a technology platform to deliver to farmers natural tools to improve crop yield, protect against insect and disease pressures while improving crop quality and reducing impact on the environment.

CEO: Stephen Kahn
Founder(s): Tom Laurita and Steve Kahn
First investment: July 2017

Pairwise_Primary_Logo

Pairwise

Vision

Healthy food should be affordable, convenient, and sustainable.

Approach

Pairwise brings together leaders in agriculture and technology to harness the potential of genome editing to address consumers’ and farmers’ needs. From developing novel genome editing tools to leveraging the natural genetic diversity of plants, Pairwise is working to deliver breakthrough innovation.

CEO: Tom Adams
Founder(s): Tom Adams, Haven Baker, Dr. David Liu, Dr. Feng Zhang, and Dr. J. Keith Joung
First investment: July 2017

farmlead_logo-white

FarmLead

Vision

FarmLead aims to facilitate greater equality, efficiency, and transparency in grain marketing.

Approach

The FarmLead platform re-invents how grain marketing is done through the world’s fastest growing online grain marketplace.

CEO: Brennan Turner
Founder(s): Alain Goubau and Brennan Turner
First investment: December 2016

resson_logo

Resson

Approach

Resson is a bioinformatics and predictive analytics company that uses large scale data analytics, together with drones and swarm robotics, to help large and small agriculture companies, agricultural service providers and individual growers boost productivity and profits with near real-time predictive analysis for crop management.

First investment: April 2016

understory

Understory

Approach

Understory is the first company to successfully offer parametric insurance products for severe weather risk, protecting farmers and others in climate-vulnerable industries. The company's growing network of ground-based Dot weather sensors, combined with its Atmospheric Intelligence AI, allow the company to assess and price any weather risk in the world. When severe weather strikes, Understory detects it and triggers a fast, predetermined payout. Ultimately, Understory allows capital to flow quickly where it’s needed most after a weather disaster.

CEO: Alex Kubicek
Founder(s): Alex Kubicek and Bryan Dow
First investment: January 2016

plant_response_logo

Plant Response

Vision

To contribute to the developing of a sustainable agriculture that helps feed the planet and respects health and the environment.

Approach

Plant Response strives to pioneer better plant innate immunity, plant physiology, and nutrient use efficiency. Using its expertise in plant science, the company seeks to understand key crop challenges, develop sustainable solutions, and address challenges by aligning pioneering research and current market needs.

CEO: Tom Snipes
Founder(s): Dr. Antonio Molina Fernández and Dr. Pablo Rodríguez Palenzuela
First investment: August 2015

CoverCress_logo

Covercress

Approach

CoverCress seeks a better future for crop fields by developing weather-resistant cover crops that can grow in a region's off season. More effective cover crops will allow the industry to better protect, maintain, and improve soil quality while boosting disease and pest management.

CEO: Jerry Steiner
Founder(s): Jerry Steiner and Dr. Tim Ulmasov
First investment: May 2015

agbiome_logo

AgBiome

Approach

AgBiome focuses its R&D efforts on the plant and soil microbiome to deliver innovative crop solutions. The plant and soil microbiomes are complex naturally occurring communities of billions of organisms essential to life. By taking advantage of the untapped benefits of these organisms, AgBiome is discovering new solutions that work symbiotically with a plant, resulting in robust and sustainable crops.

CEO: Scott Uknes
Founder(s): Scott Uknes, Eric Ward, Prof. Jeff Dangl, Prof. Paul Schulze-Lefert , John Ryals, and Mike Koziel
First investment: December 2012